Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP-14 versus R-CHOP-21 with darbepoetin alfa prophylaxis in older untreated CD20-positive diffuse large B-cell lymphoma
2007-001519-52Phase 3Completed
- Sponsor
- LYSA
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of darbepoetin alfa, rituximab, cyclophosphamide, doxorubicin, vincristine and 1 more in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by LYSA. Primary endpoint: Event-free survival. Started Sep 2007; status: completed.
02
Drugs
darbepoetin alfarituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2007-001519-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001519-52.